Alaunos Therapeutics (TCRT) director gets 8,789-share equity grant in lieu of fees
Rhea-AI Filing Summary
Vieser Jaime reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics, Inc. director Jaime Vieser reported an equity compensation grant of 8,789 shares of common stock on 2026-07-23, valued at $1.92 per share and issued in lieu of board fees. Following this award, he holds 47,642 shares directly. The report also lists indirect holdings of 2,100 shares held by his children and 13,503 shares held by Brushwood LLC, where he serves as Manager.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 8,789 shares
Net Buy
3 txns
Insider
Vieser Jaime
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 8,789 | $1.92 | $17K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F2 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 47,642 shares (Direct);
Common Stock — 2,100 shares (Indirect, by Reporter's children);
Common Stock — 13,503 shares (Indirect, By Brushwood LLC)
Footnotes (2)
- F1. Represents shares of common stock issued in lieu of board fees.
- F2. The shares are directly held by Brushwood LLC. The Reporting Person is the Manager of Brushwood LLC.
Key Figures
Shares granted: 8,789 shares
Grant price: $1.92 per share
Direct holdings after grant: 47,642 shares
+2 more
5 metrics
Shares granted
8,789 shares
Common stock grant issued in lieu of board fees on 2026-07-23
Grant price
$1.92 per share
Valuation used for the 8,789-share common stock grant
Direct holdings after grant
47,642 shares
Total common stock directly held by Jaime Vieser following the award
Indirect holdings (children)
2,100 shares
Common stock held indirectly by the reporter's children
Indirect holdings (Brushwood LLC)
13,503 shares
Common stock held indirectly through Brushwood LLC, managed by the reporter
Key Terms
issued in lieu of board fees, indirect ownership, Manager of Brushwood LLC
3 terms
issued in lieu of board fees financial
"Represents shares of common stock issued in lieu of board fees."
indirect ownership financial
"The shares are indirectly held, including by the reporter's children and Brushwood LLC."
Manager of Brushwood LLC financial
"The shares are directly held by Brushwood LLC. The Reporting Person is the Manager of Brushwood LLC."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Alaunos Therapeutics (TCRT) director Jaime Vieser report?
Jaime Vieser reported a grant of 8,789 shares of Alaunos Therapeutics common stock on 2026-07-23. The shares were issued in lieu of board fees and increased his directly held position to 47,642 shares.
What are Jaime Vieser’s total direct and indirect Alaunos Therapeutics (TCRT) holdings after the grant?
After the grant, he holds 47,642 shares directly. Indirectly, the report lists 2,100 shares held by his children and 13,503 shares held by Brushwood LLC, where he is the Manager, in addition to his direct holdings.
Does the Alaunos Therapeutics (TCRT) Form 4 indicate use of a Rule 10b5-1 trading plan?
No. The report’s Rule 10b5-1 checkbox is not marked as affirming that the transactions were made under a Rule 10b5-1 trading plan. The grant is characterized instead as stock issued in lieu of board fees.
How are the Brushwood LLC holdings in Alaunos Therapeutics (TCRT) attributed in the report?
The report shows 13,503 shares held indirectly through Brushwood LLC. A footnote explains the shares are directly held by Brushwood LLC and that Jaime Vieser is the Manager of Brushwood LLC, linking him to that position.